{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-24-000026","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.667165+00:00","generated_at":"2026-06-05T04:52:14.698269+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Humacyte prices $40.2M public offering of 13.4M shares at $3.00 per share","bullets":["Offering of 13,400,000 shares at $3.00/share; gross proceeds $40.2M before underwriting discounts.","Underwriters have 30-day option to buy up to 2,010,000 additional shares.","Net proceeds ~$37.4M (or ~$43.1M if option exercised); closing expected March 5, 2024.","Proceeds to fund BLA for HAVs in vascular trauma, pipeline advancement, and commercial infrastructure.","TD Cowen and Cantor are joint book-running managers; BTIG is lead manager."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-24-000026","json":"https://secwatch.observer/filing/0001818382-24-000026.json","markdown":"https://secwatch.observer/filing/0001818382-24-000026.md","text":"https://secwatch.observer/filing/0001818382-24-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000026/0001818382-24-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000026/huma-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:52:14.698269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0f0768b29800e3283f2bac1ec8c5fe47783b324","claim":"Humacyte, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein valued at approximately $37.4 million (effective 2024-02-29).","evidence_excerpt":"On February 29, 2024, Humacyte, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) of 13,400,000 shares of the Company’s common stock, $0.0001 par value per share, at a price to the public of $3.00 per share (the “Firm Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000181838224000026/0001818382-24-000026-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Cowen and Company, LLC and Cantor Fitzgerald & Co. as representatives of the several underwriters named therein"},{"label":"Value","value":"approximately $37.4 million"},{"label":"Effective","value":"2024-02-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}